Trials / Completed
CompletedNCT00393146
A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis
A Randomized, Double Blind, Placebo Controlled Study to Investigate the Safety and Tolerability and Clinical Activity of 28 Days of Oral Repeat Dosing With GW856553 at 7.5mg BID in Subjects With Active Rheumatoid Arthritis on Stable Anti-rheumatic Therapy.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to look at the safety, tolerability and effectiveness of 28 days of dosing of GW856553 in rheumatoid arthritis patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW856553 | Study drug |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2006-10-26
- Last updated
- 2015-05-13
Locations
15 sites across 3 countries: Romania, Russia, Spain
Source: ClinicalTrials.gov record NCT00393146. Inclusion in this directory is not an endorsement.